Alar Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2.75	5.82	469.27	0.8	-
Revenue Growth (YoY)	-52.67%	-98.76%	58559.00%	-	-
Cost of Revenue	0.61	2.03	-	-	-
Gross Profit	2.14	3.79	469.27	0.8	-
Selling, General & Admin	13.43	14.39	27.03	13.15	11.41
Research & Development	156.51	57.34	56.71	34.18	81.89
Operating Expenses	169.94	71.73	83.75	47.33	93.3
Operating Income	-167.8	-67.94	385.53	-46.53	-93.3
Interest Expense	-0.08	-0.03	-0.06	-0.02	-0.02
Interest & Investment Income	54.52	66.31	16.92	2.79	1.5
Earnings From Equity Investments	-0.75	-8.54	-	-	-
Currency Exchange Gain (Loss)	24.7	46.72	-11.32	1.67	0.07
Other Non Operating Income (Expenses)	0.64	0.53	0.04	9.55	27.52
EBT Excluding Unusual Items	-88.75	37.05	391.11	-32.54	-64.23
Gain (Loss) on Sale of Investments	9.78	-	-	-	-
Pretax Income	-78.97	37.05	391.11	-32.54	-64.23
Income Tax Expense	0.71	18.88	8.49	-12.67	-
Net Income	-79.68	18.17	382.62	-19.87	-64.23
Net Income to Common	-79.68	18.17	382.62	-19.87	-64.23
Net Income Growth	-	-95.25%	-	-	-
Shares Outstanding (Basic)	67	66	57	57	57
Shares Outstanding (Diluted)	67	66	57	57	57
Shares Change (YoY)	0.87%	16.08%	0.09%	-	14.21%
EPS (Basic)	-1.19	0.27	6.71	-0.35	-1.13
EPS (Diluted)	-1.19	0.27	6.71	-0.35	-1.13
EPS Growth	-	-95.98%	-	-	-
Free Cash Flow	-173.9	-107.44	397.23	-34.09	-65.05
Free Cash Flow Per Share	-2.60	-1.62	6.96	-0.60	-1.14
Dividend Per Share	0.100	0.250	1.500	-	-
Dividend Growth	-60.00%	-83.33%	-	-	-
Gross Margin	77.73%	65.15%	100.00%	100.00%	-
Operating Margin	-6095.10%	-1168.02%	82.15%	-5815.88%	-
Profit Margin	-2894.41%	312.36%	81.53%	-2483.88%	-
Free Cash Flow Margin	-6316.67%	-1846.95%	84.65%	-4260.75%	-
EBITDA	-165.35	-65.43	387.58	-44.16	-90.82
EBITDA Margin	-	-	82.59%	-	-
D&A For EBITDA	2.45	2.51	2.05	2.36	2.48
EBIT	-167.8	-67.94	385.53	-46.53	-93.3
EBIT Margin	-	-	82.15%	-	-
Effective Tax Rate	-	50.96%	2.17%	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.